"FDA Panel Recommends Streamlined Flu Vaccine Revision After COVID-19 Impact"
FDA experts have recommended changes to flu vaccines, suggesting that quadrivalent flu vaccines be converted into trivalent vaccines for the 2024–2025 season to only reflect currently circulating viral strains, potentially increasing vaccine supplies. The removal of the B/Yamagata lineage component from the vaccines could boost annual production capacity from ~500M doses of quadrivalent shots to 700M trivalent vaccines, with flu vaccine makers like GSK, Sanofi, CSL Limited, and AstraZeneca involved. Additionally, drugmakers such as Pfizer/BioNTech, Moderna, and Novavax are studying combined flu and COVID vaccines.